Diagnosing a pituitary disorder typically involves a combination of blood hormone panels, specialized stimulation or suppression tests, MRI imaging, and sometimes vision testing. Because the pituitary gland controls so many hormonal systems, there’s no single test that covers everything. The specific workup depends on whether doctors suspect the gland is producing too much of a hormone, too little, or whether a mass is pressing on nearby structures.
Baseline Hormone Blood Tests
The first step is almost always a comprehensive blood draw that measures the hormones your pituitary produces, along with the hormones from the glands it controls. A standard panel includes prolactin, IGF-1 (a liver hormone that reflects growth hormone output), cortisol and ACTH (the stress hormone pair), thyroid function through free T4 and TSH, and the sex hormones testosterone, estrogen, LH, and FSH. These are typically drawn in the morning, when many pituitary hormones follow predictable daily patterns.
What makes pituitary testing tricky is that you can’t always interpret one hormone in isolation. The pituitary works in feedback loops with its target glands. A low thyroid hormone with a low or normal TSH, for example, points toward a pituitary problem rather than a thyroid one. A straightforward thyroid issue would show TSH moving in the opposite direction. Doctors look at these pairs together to figure out where the system is breaking down.
Testing for Growth Hormone Problems
Growth hormone is one of the harder pituitary hormones to measure directly because it’s released in pulses throughout the day. Instead, doctors measure IGF-1, which stays more stable in the blood and reflects your overall growth hormone activity.
Too Much Growth Hormone (Acromegaly)
If IGF-1 is more than 1.3 times the upper limit of normal for your age, that confirms acromegaly in someone who already has the typical signs like enlarged hands, feet, or facial features. When results are borderline, doctors use an oral glucose tolerance test: you drink a sugary solution containing 75 grams of glucose after fasting, and your growth hormone is measured at 30, 60, 90, and 120 minutes. In a healthy person, the sugar load suppresses growth hormone. In acromegaly, it doesn’t.
Too Little Growth Hormone
Diagnosing growth hormone deficiency requires the opposite approach: a stimulation test. The gold standard is the insulin tolerance test, where insulin is injected to deliberately lower your blood sugar below 40 mg/dL. This should trigger a strong growth hormone release. If your peak growth hormone stays at or below 5 µg/L during the test, that confirms deficiency. The test requires medical supervision because of the intentional low blood sugar, and it’s not appropriate for people with seizure disorders or heart conditions.
For patients who can’t safely undergo the insulin test, a glucagon stimulation test is the main alternative. The diagnostic cutoff depends on body weight. For people at a normal weight, a peak growth hormone of 3 µg/L or below confirms deficiency. For people with obesity (BMI over 30), the cutoff drops to 1 µg/L, because excess body fat naturally blunts the growth hormone response and would otherwise cause false positives.
Diagnosing High Prolactin
Prolactin is the one pituitary hormone that can be reliably diagnosed from a simple blood draw, since it doesn’t fluctuate as dramatically as growth hormone. But interpreting the number matters. A prolactin level above 150 ng/mL in someone with a pituitary mass strongly suggests a prolactin-producing tumor (prolactinoma). Historically, levels above 200 ng/mL were considered the definitive threshold, though more recent studies have proposed lower cutoffs in the range of 39 to 56 ng/mL for smaller tumors.
This distinction is clinically important. Many pituitary tumors that don’t produce prolactin can still push prolactin levels mildly upward by compressing the pituitary stalk, which disrupts the normal signal that keeps prolactin in check. These “stalk effect” elevations rarely push prolactin above 100 to 120 ng/mL. So a very high prolactin level points toward a true prolactinoma, while a modestly elevated level alongside a large mass could mean something else entirely, requiring a different treatment approach.
Cushing’s Disease: Confirming Cortisol Excess
Cushing’s disease, caused by a pituitary tumor that overproduces ACTH, is one of the most difficult pituitary disorders to pin down. Screening typically starts with tests that check whether your body is making too much cortisol: a 24-hour urine collection, late-night salivary cortisol measurements, or a low-dose dexamethasone suppression test where you take a small steroid pill at night and check whether your morning cortisol drops appropriately.
Once excess cortisol is confirmed and blood work shows ACTH is elevated (meaning the problem is driven by ACTH rather than the adrenal glands acting on their own), the next challenge is figuring out whether that ACTH is coming from the pituitary or from a tumor elsewhere in the body. This is where inferior petrosal sinus sampling comes in. Catheters are threaded through veins to the drainage channels right next to the pituitary, and ACTH levels are measured there and compared to a sample from a peripheral vein. If the ratio of ACTH near the pituitary to ACTH in the peripheral blood is greater than 2 at baseline, or greater than 3 after stimulation with a hormone called CRH, the source is confirmed as the pituitary. Ratios below those thresholds point toward an ectopic source somewhere else in the body.
MRI: The Imaging Gold Standard
MRI is the primary imaging tool for evaluating the pituitary gland, offering far better soft tissue detail than CT scans in this small, anatomically complex area. A standard pituitary MRI protocol includes thin slices (around 3 to 5 mm) in both coronal and sagittal planes, using T1-weighted and T2-weighted sequences.
For detecting small tumors (microadenomas, under 10 mm), dynamic contrast-enhanced MRI is considered the gold standard. A contrast agent is injected, and rapid images are captured at intervals of roughly 30 seconds over the first three minutes. Normal pituitary tissue enhances brightly and quickly, while most adenomas enhance more slowly, making them stand out as relatively dark spots in the early images. This dynamic technique is particularly valuable when standard MRI doesn’t reveal a tumor that blood work suggests should be there.
There’s growing attention to the long-term safety of repeated gadolinium contrast injections, since trace amounts of the contrast agent can accumulate in the brain over time. For follow-up imaging of known, stable tumors, some centers are moving toward non-contrast protocols, reserving dynamic contrast for the initial diagnosis or when clinical findings change.
Visual Field Testing
The pituitary gland sits just below the optic chiasm, the point where the optic nerves partially cross. When a pituitary tumor grows upward, it can compress these nerve fibers and cause characteristic vision loss, most commonly in the outer (temporal) visual fields of both eyes. This pattern is called bitemporal hemianopsia, and it often develops gradually enough that people don’t notice it until it’s fairly advanced.
Automated visual field testing (perimetry) is the standard tool for detecting this compression. It maps your ability to see lights at various points across your field of vision, picking up peripheral losses that you might not be aware of in daily life. Pituitary tumors generally don’t compress the chiasm until they extend about 8 mm or more above the top of the bony pocket where the pituitary sits. Not all large tumors cause vision problems, though. The exact anatomy varies from person to person, and the position of the chiasm relative to the tumor matters as much as the tumor’s size.
Water Balance: Diagnosing Diabetes Insipidus
The pituitary’s posterior lobe stores and releases a hormone that tells your kidneys to conserve water. When this system fails, you produce large volumes of very dilute urine and feel intensely thirsty, a condition called diabetes insipidus (unrelated to the more common diabetes mellitus).
The classic diagnostic test is the water deprivation test. You stop drinking fluids under medical supervision, and your urine and blood are monitored over several hours. In a healthy person, urine becomes progressively more concentrated as the body conserves water. In diabetes insipidus, urine stays dilute (below 300 mOsm/kg) even as blood becomes more concentrated (above 300 mOsm/kg) or sodium rises above 146 mmol/L.
Once the test confirms that urine isn’t concentrating properly, a synthetic version of the missing hormone (desmopressin) is given. If urine concentration jumps by more than 50%, sometimes increasing by 200% to 400%, the problem is in the pituitary: the kidneys work fine when they get the hormone they’ve been missing. If desmopressin has little effect, the kidneys themselves aren’t responding, pointing to a different condition called nephrogenic diabetes insipidus. Partial forms of both types exist, where urine osmolality after water deprivation lands between 300 and 800 mOsm/kg and the response to desmopressin is less dramatic, making the diagnosis more nuanced.
Putting the Pieces Together
Pituitary disorders are rarely diagnosed by a single test. The process typically starts with blood work that flags a hormonal imbalance, followed by confirmatory dynamic testing (stimulation or suppression), imaging to look for a structural cause, and functional assessments like vision testing when a mass is large enough to threaten nearby structures. Each layer of testing narrows the diagnosis and shapes the treatment plan. Because many of these tests require specific timing, fasting, or medical supervision, the full workup often unfolds over several appointments with an endocrinologist rather than happening all at once.